Specialty drug coverage works differently from ordinary prescription coverage at almost every step: the drug sits on your plan’s highest formulary tier, your insurer requires prior approval before paying, you pay a percentage of the price rather than a flat copay, and the medication is dispensed through a designated specialty pharmacy rather than your local drugstore. Understanding how specialty drug coverage works matters because these medications routinely cost thousands of dollars a month, and the rules governing them determine both whether you get the drug and what you pay for it.
What Counts as a Specialty Drug
Insurers and pharmacy benefit managers classify a drug as “specialty” using a mix of cost, complexity, and the condition it treats. Medicare Part D gives the clearest benchmark: CMS sets a monthly ingredient-cost threshold each year, and drugs priced above that line can be placed on a plan’s specialty tier. Commercial insurers use their own cost-based cutoffs, generally following similar logic.
Price isn’t the only factor. Specialty drugs typically require complex administration — subcutaneous injections, intravenous infusions, or clinical monitoring beyond swallowing a pill. Many are biologics that need cold-chain shipping held between 36 and 46 degrees Fahrenheit from manufacturer to patient. The conditions treated are often rare or chronic diseases where standard treatments have failed, including rheumatoid arthritis, multiple sclerosis, hepatitis C, and various cancers.1eCFR. 21 CFR Part 316 – Orphan Drugs
Which Part of Your Plan Pays
Specialty drugs run through one of two parts of your insurance, and which one applies changes both your out-of-pocket cost and how you receive the drug.
Drugs administered in a clinical setting — chemotherapy infusions at a cancer center, biologic injections at a rheumatologist’s office — typically fall under your medical benefit. Claims are processed using Healthcare Common Procedure Coding System codes that cover both the drug and the administration service.2Centers for Medicare & Medicaid Services. Healthcare Common Procedure Coding System (HCPCS)
Self-administered medications, like oral tablets or pre-filled injection pens you use at home, usually go through the pharmacy benefit and are dispensed through specialty pharmacies.3U.S. Food and Drug Administration. National Drug Code Directory Deductibles, coinsurance rates, and out-of-pocket maximums can differ between the two benefits within the same plan.
Some insurers shift drugs from the medical benefit to the pharmacy benefit through “white bagging,” where a specialty pharmacy ships the drug directly to a doctor’s office, or “brown bagging,” where you pick up the drug yourself and bring it to your appointment. Both let insurers capture pharmacy benefit pricing. Brown bagging raises handling concerns for drugs that require tight temperature control.
Prior Authorization and Step Therapy
Nearly every specialty drug requires prior authorization. Your physician’s office handles most of the paperwork, but you should know what’s being submitted so you can push the process along if it stalls.
The Clinical File
The prior authorization request is a clinical argument that you need this specific drug. Your doctor submits diagnostic codes matching the drug’s approved uses, lab results or test reports that show you meet the biological criteria (genetic testing, biopsies, imaging), and evidence that you’ve already tried and failed less expensive treatments or that those alternatives are medically inappropriate. Incomplete forms are the most common cause of delay.
Response Timelines
Under the CMS Interoperability and Prior Authorization final rule taking effect in 2026, covered payers must decide urgent requests within 72 hours and standard requests within seven calendar days.4Centers for Medicare & Medicaid Services. Prior Authorization API This applies to Medicare Advantage, Medicaid managed care, CHIP, and qualified health plans on the federal marketplace. Employer-sponsored plans not subject to the rule often follow similar timelines voluntarily; check your plan documents.
Step Therapy
Even with a specific prescription, your insurer may require you to try cheaper alternatives first. This is step therapy, sometimes called “fail first.” Some plans require one prior medication, others require two or three, and the trial period for each can run three to six months. Most states have passed override laws that let you skip these requirements if you’ve already tried and failed the required drug (even under a previous plan), if the required drug is medically dangerous for you, if you have a condition like metastatic cancer where delays are harmful, or if you’re stable on your current medication. Your doctor can request an exception, and these protections give you leverage when a denial arrives.
What You’ll Pay
Specialty drugs sit on the highest tier of your plan’s formulary, typically labeled Tier 4 or the “specialty tier.”5Medicare.gov. How Do Drug Plans Work Unlike lower tiers with a flat $20 or $50 copay, the specialty tier almost always uses coinsurance, meaning you pay a percentage of the drug’s negotiated price. In Medicare Part D, specialty-tier coinsurance ranges from 25% to 33%. In commercial plans, it can run higher. When a drug costs $10,000 a month, 25% coinsurance is $2,500 for a single fill.
The safety net is your plan’s annual out-of-pocket maximum. Once your deductible, copays, and coinsurance reach that limit, the plan covers 100% of remaining costs for the year. For 2026, the ACA caps the maximum at $10,600 for individual coverage and $21,200 for family coverage in marketplace and most employer plans.6HealthCare.gov. Out-of-Pocket Maximum/Limit That ceiling is real protection, but if you’re on a specialty drug, you can hit it within the first month or two of the plan year.
Site-of-Care Rules
Where you receive an infused specialty drug affects what you pay. Insurers increasingly require that infusions happen at freestanding infusion centers or at home rather than in a hospital outpatient department. The same drug infused at a hospital may cost two or three times what it costs at an independent infusion center, and your coinsurance percentage applies to the higher amount. If your insurer mandates a site change, the prior authorization may need to be resubmitted with the new provider, so plan for a possible gap.
Medicare Part D: The Annual Cap
If your coverage is Medicare, the Inflation Reduction Act changed the math. Starting in 2025, Part D out-of-pocket spending was capped at $2,000 per year. For 2026, the cap is $2,100, indexed to per-capita Part D spending growth.7Centers for Medicare & Medicaid Services. Final CY 2026 Part D Redesign Program Instructions Before this change, Medicare enrollees on specialty drugs could face $10,000 or more in annual out-of-pocket costs.
Hitting even $2,100 in the first month of the year is a strain, so all Part D plans must now offer the Medicare Prescription Payment Plan. This spreads your out-of-pocket drug costs across monthly installments instead of charging the full coinsurance at the pharmacy counter.8Centers for Medicare & Medicaid Services. Medicare Prescription Payment Plan You still owe the same total; the cash flow is just manageable.
Lowering What You Pay
Manufacturer Assistance
Most specialty drug manufacturers offer copay cards or patient assistance programs that sharply reduce what you pay at the pharmacy, often to a nominal amount. Eligibility and coverage vary. Many programs exclude Medicare and Medicaid beneficiaries because federal anti-kickback rules restrict manufacturer payments on government-funded prescriptions. If you have commercial insurance, ask your specialty pharmacy about available programs before your first fill.
Biosimilars
If your specialty drug is a biologic, a biosimilar may be available at substantially lower cost. Biosimilars are FDA-approved alternatives to brand-name biologics, manufactured to be highly similar with no clinically meaningful differences in safety or effectiveness. The FDA has approved over 90 biosimilars, and average sales prices run roughly 50% below the reference biologic at launch.9U.S. Department of Health and Human Services. Bringing Lower-Cost Biosimilar Drugs to American Patients Some biosimilars are designated “interchangeable,” meaning a pharmacist can substitute them for the reference product without your doctor’s involvement. Ask your doctor whether one exists for your drug.
The Copay Accumulator Trap
Some plans use copay accumulator programs that accept manufacturer copay assistance at the pharmacy counter — so you pay little or nothing for each fill — but don’t count that assistance toward your annual deductible or out-of-pocket maximum.10Centers for Medicare & Medicaid Services. Out-of-Pocket Maximum/Limit When the manufacturer’s assistance runs out, often mid-year, you suddenly owe full coinsurance and you haven’t made any progress toward your out-of-pocket cap. Roughly 25 states and the District of Columbia have banned or restricted these programs for state-regulated plans. Self-funded employer plans governed by federal ERISA law are generally exempt from those state bans. Look through your plan’s Summary of Benefits and Coverage for language about “copay adjustment” or “accumulator” programs before assuming manufacturer help will carry you through the full year.
If Your Insurer Denies the Drug
A denial isn’t the end. Federal law gives you a structured right to challenge it, and specialty drug appeals succeed more often than patients expect when the clinical documentation is strong.
Internal Appeal
You have at least 180 days from the denial to file an internal appeal. You can submit additional evidence, updated lab results, or a letter of medical necessity from your physician. The insurer must assign the review to someone who wasn’t involved in the original denial, and the adjudicator’s compensation cannot be tied to the likelihood of upholding denials.11eCFR. 45 CFR 147.136 – Internal Claims and Appeals and External Review Processes The insurer must respond within 72 hours for urgent requests, 30 days for pre-treatment requests, and 60 days for claims submitted after treatment. If the insurer fails to follow these procedures, you’re considered to have exhausted the internal process and can go directly to external review.
External Review
If the internal appeal fails, you can request an external review. An independent review organization — not your insurer — evaluates the denial. External review applies to any denial involving medical judgment, including whether a drug is medically necessary, appropriate, or experimental. You have four months from the date of the final internal denial to file.11eCFR. 45 CFR 147.136 – Internal Claims and Appeals and External Review Processes Standard reviews require a written decision within 45 days. Urgent reviews require a decision within 72 hours. The external reviewer’s decision is binding on your insurer.
Working With a Specialty Pharmacy
Once your drug is approved, you won’t fill it at a retail pharmacy. Your insurer designates one or more specialty pharmacies, and you’re required to use them. A representative will contact you to arrange delivery, confirm your copay or coinsurance, and walk you through side effects, injection technique if applicable, and home storage.
Specialty pharmacies ship temperature-controlled packages directly to your home or, for drugs administered in a clinical setting, to your doctor’s office. Most provide ongoing adherence support: check-in calls, refill reminders, and coordination with your physician if problems arise.
Expect your specialty pharmacy to initiate refill coordination well before your current supply runs out. These drugs often have limited inventory and may require reauthorization after a set number of fills. Waiting until you’re out of medication to call risks a gap in treatment. If you’re traveling or need delivery rescheduled, give the pharmacy as much lead time as possible, because cold-chain shipping doesn’t accommodate last-minute changes well.
Switching Plans Without Breaking Your Treatment
Changing insurance plans while on a specialty drug is one of the highest-risk moments for treatment disruption. Your new plan may not cover the same drug, may require a fresh prior authorization, or may mandate a different specialty pharmacy. During open enrollment or a qualifying life event, check the new plan’s formulary for your specific drug before you commit.
Most plans offer a transition of care process for patients already established on a treatment. You typically need to apply within 30 days of your new coverage effective date. Approval usually provides continued access to your current drug and provider for a temporary period, often around 90 days, while you and your doctor work through new prior authorization or formulary requirements. A separate medical necessity review may still be required during that window. File the transition request on day one of your new plan. For some conditions, interrupting treatment reduces the drug’s effectiveness when you restart.